11 月 3 日,药物临床试验登记与信息公示平台官网显示,恒瑞登记了一项SHR-8068 联合阿得贝利单抗及含铂化疗对比度伐利尤单抗联合含铂化疗一线治疗晚期胆道癌(BTC)的 III 期临床研究。截图来源:药物临床试验登记与信息公示平台这是一项随机、开放、对照、多中心 III 期研究,旨在通过盲态独立审评中心(BICR)评估的PFS 和 OS,评价 SHR-8068 联合阿得贝利单抗及含铂化疗对比...
Source Link11 月 3 日,药物临床试验登记与信息公示平台官网显示,恒瑞登记了一项SHR-8068 联合阿得贝利单抗及含铂化疗对比度伐利尤单抗联合含铂化疗一线治疗晚期胆道癌(BTC)的 III 期临床研究。截图来源:药物临床试验登记与信息公示平台这是一项随机、开放、对照、多中心 III 期研究,旨在通过盲态独立审评中心(BICR)评估的PFS 和 OS,评价 SHR-8068 联合阿得贝利单抗及含铂化疗对比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.